-
公开(公告)号:US07411073B2
公开(公告)日:2008-08-12
申请号:US10544899
申请日:2004-02-20
申请人: Amjad Ali , Richard Beresis , Steven L. Colletti , Donald W. Graham , James R. Tata , Christopher F. Thompson
发明人: Amjad Ali , Richard Beresis , Steven L. Colletti , Donald W. Graham , James R. Tata , Christopher F. Thompson
IPC分类号: C07D231/54 , A01N43/56
CPC分类号: C07D409/12 , C07D231/54 , C07D401/12 , C07D403/06 , C07D403/12 , C07D409/04
摘要: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括式(I)化合物或其药学上可接受的盐或水合物,其可用作新型非甾体选择性糖皮质激素受体调节剂,用于治疗多种自身免疫性和炎性疾病或病症,并且具有超过甾族糖皮质激素配体的优点, 尊重不良的副作用,功效,毒性和/或代谢。 还包括药物组合物和使用方法。
-
12.1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators 失效
标题翻译: 1h-苯并{f}吲唑-5-基衍生物作为选择性糖皮质激素受体调节剂公开(公告)号:US07282591B2
公开(公告)日:2007-10-16
申请号:US10508897
申请日:2003-04-08
IPC分类号: C07D487/14
CPC分类号: C07D417/06 , C07D231/54 , C07D401/06 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06
摘要: The present invention encompasses compounds of Formula I: (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharamaceutical compositions and methods of use are also included.
摘要翻译: 本发明包括式I化合物:(I)或其药学上可接受的盐或水合物,其可用作治疗各种自身免疫性和炎性疾病或病症的选择性糖皮质激素受体配体。 还包括制药组合物和使用方法。
-
公开(公告)号:US09486448B2
公开(公告)日:2016-11-08
申请号:US15026267
申请日:2014-09-29
申请人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
发明人: Kenneth Jay Barr , Mark E. Scott , Christopher F. Thompson , Neville Anthony , Carolyn Michele Cammarano , Raman Kumar Bakshi , Subhendu Kumar Mohanty , Chandra Sekhar Korapala , Prashant R. Latthe , Vyjayanthi N. Kambam , Sujit Kumar Sarkar , Jayanth Thiruvellore Thatai
IPC分类号: C07C53/06 , C07C53/18 , C07D401/06 , C07D401/14 , C07D413/14 , C07D471/04 , A61K31/444 , A61K31/4439 , A61K31/497 , A61K31/501 , C07D495/04 , A61K31/519 , A61K31/517
CPC分类号: A61K31/4439 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K45/06 , C07B2200/07 , C07C53/06 , C07C53/18 , C07D207/08 , C07D207/09 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04 , C07D495/04 , A61K2300/00
摘要: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译: 本发明提供式(I)化合物,其药物组合物及其用于治疗或预防由β3肾上腺素受体激活介导的疾病的方法。
-
公开(公告)号:US08604038B2
公开(公告)日:2013-12-10
申请号:US13392282
申请日:2010-08-24
申请人: Scott D. Edmondson , Lehua Chang , Nam Fung Kar , Gergori J. Morriello , Christopher R. Moyes , Dong-Ming Shen , Cheng Zhu , Neville J. Anthony , Philip Jones , Graham F. Smith , Mark E. Scott , Christopher F. Thompson , Joon Jung , Carolyn Cammarano , Dawn Marie Hoffman
发明人: Scott D. Edmondson , Lehua Chang , Nam Fung Kar , Gergori J. Morriello , Christopher R. Moyes , Dong-Ming Shen , Cheng Zhu , Neville J. Anthony , Philip Jones , Graham F. Smith , Mark E. Scott , Christopher F. Thompson , Joon Jung , Carolyn Cammarano , Dawn Marie Hoffman
IPC分类号: A61K31/50 , A61K31/525
CPC分类号: C07D401/12 , C07D207/08 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译: 本发明提供式(I)的化合物,其药物组合物及其用于治疗或预防由β3肾上腺素受体激活介导的疾病的方法。
-
15.NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS 有权
标题翻译: 新型吡咯烷衍生的BETA 3 ADRENERGIC RECEPTOR AGONISTS公开(公告)号:US20120225886A1
公开(公告)日:2012-09-06
申请号:US13392282
申请日:2010-08-24
申请人: Scott D. Edmondson , Lehua Chang , Nam Fung Kar , Gregori J. Morriello , Christopher R. Moyes , Dong-Ming Shen , Cheng Zhu , Neville J. Anthony , Philip Jones , Graham F. Smith , Mark E. Scott , Christopher F. Thompson , Joon Jung , Carolyn Cammarano , Dawn Marie Hoffman
发明人: Scott D. Edmondson , Lehua Chang , Nam Fung Kar , Gregori J. Morriello , Christopher R. Moyes , Dong-Ming Shen , Cheng Zhu , Neville J. Anthony , Philip Jones , Graham F. Smith , Mark E. Scott , Christopher F. Thompson , Joon Jung , Carolyn Cammarano , Dawn Marie Hoffman
IPC分类号: A61K31/501 , A61K31/4196 , C07D401/12 , A61K31/4439 , A61K31/506 , A61K31/497 , C07D417/12 , A61K31/427 , C07D413/12 , A61K31/422 , C07D471/04 , A61K31/437 , C07D207/04 , A61K31/40 , A61P13/10 , A61P13/02 , C07D403/12
CPC分类号: C07D401/12 , C07D207/08 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译: 本发明提供式(I)化合物,其药物组合物及其用于治疗或预防由β-肾上腺素能受体激活介导的疾病的方法。
-
16.
公开(公告)号:US20160272634A1
公开(公告)日:2016-09-22
申请号:US14778055
申请日:2014-03-19
申请人: Christopher DINSMORE , Peter FULLER , David GUERIN , Jason David KATZ , Christopher F. THOMPSON , Danielle FALCONE , Wei DENG , Luis TORRES , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , Mark E. SCOTT , MERCK SHARP & DOHME CORP.
发明人: Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Christopher F. Thompson , Danielle Falcone , Wei Deng , Luis Torres , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng , Mark E. Scott
IPC分类号: C07D471/04 , C07D519/00
CPC分类号: C07D471/04 , C07D519/00
摘要: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
摘要翻译: 本发明提供了作为JAK抑制剂的式I化合物,因此可用于治疗JAK介导的疾病如类风湿性关节炎,哮喘,COPD和癌症。
-
17.N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
标题翻译: N-(2-氰基杂环基)吡唑并吡喃酮作为甘薯激酶抑制剂公开(公告)号:US20160272633A1
公开(公告)日:2016-09-22
申请号:US14778052
申请日:2014-03-19
申请人: Christopher DINSMORE , Peter FULLER , David GUERIN , Christopher F. THOMPSON , Qinglin PU , Mark E. SCOTT , Jason David KATZ , Ravi KURUKLASURIYA , Joshua T. CLOSE , Danielle FALCONE , Jason BRUDAKER , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , MERCK SHARP & DOHME CORP.
发明人: Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kuruklasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC分类号: C07D471/04 , C07D519/00
CPC分类号: C07D471/04 , C07D519/00
摘要: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
-
公开(公告)号:US09221834B2
公开(公告)日:2015-12-29
申请号:US13881896
申请日:2011-10-25
申请人: Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
发明人: Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
IPC分类号: A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/4545 , A61K31/497 , A61K31/444 , C07D491/08 , C07D417/14 , C07D413/14 , A61K31/42 , A61K45/06 , C07D413/06
CPC分类号: C07D491/08 , A61K31/42 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D413/06 , C07D413/14 , C07D417/14 , A61K2300/00
摘要: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
摘要翻译: 具有式I结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于培养HDL-胆固醇,降低LDL-胆固醇,以及用于治疗或预防动脉粥样硬化。 在式I的化合物中,A3是取代的苯基或茚满基。 式(I)。
-
公开(公告)号:US08735435B2
公开(公告)日:2014-05-27
申请号:US12625783
申请日:2009-11-25
申请人: Amjad Ali , Joann M. Napolitano , Qiaolin Deng , Zhijian Lu , Peter J. Sinclair , Gayle E. Hallett , Christopher F. Thompson , Nazia Quraishi , Cameron J. Smith
发明人: Amjad Ali , Joann M. Napolitano , Qiaolin Deng , Zhijian Lu , Peter J. Sinclair , Gayle E. Hallett , Christopher F. Thompson , Nazia Quraishi , Cameron J. Smith
IPC分类号: C07D263/04 , A61K31/421
CPC分类号: C07F7/10 , A61K31/4015 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D207/26 , C07D207/27 , C07D233/32 , C07D233/38 , C07D233/50 , C07D233/52 , C07D263/04 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D285/06 , C07D285/10 , C07D401/04 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04 , C07D417/10
摘要: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
摘要翻译: 具有式I结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于升高HDL-胆固醇,降低LDL-胆固醇,以及用于治疗或预防动脉粥样硬化。在式I化合物中,B或 R2是具有邻芳基,杂环,苯并杂环或苯并环烷基取代基的苯基,并且在5元环上的另一个位置具有直接连接到环上或连接到环上的芳族,杂环,环烷基,苯并杂环或苯并环烷基取代基 通过-CH2-。
-
公开(公告)号:US20130331372A1
公开(公告)日:2013-12-12
申请号:US13881896
申请日:2011-10-25
申请人: Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
发明人: Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
IPC分类号: C07D491/08 , A61K31/5377 , A61K31/4545 , A61K31/444 , A61K31/497 , C07D417/14 , C07D413/14 , A61K45/06 , A61K31/4439 , A61K31/506
CPC分类号: C07D491/08 , A61K31/42 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D413/06 , C07D413/14 , C07D417/14 , A61K2300/00
摘要: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
摘要翻译: 具有式I结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于培养HDL-胆固醇,降低LDL-胆固醇,以及用于治疗或预防动脉粥样硬化。 在式I的化合物中,A3是取代的苯基或茚满基。 式(I)。
-
-
-
-
-
-
-
-
-